Foghorn Therapeutics (FHTX) Expected to Announce Earnings on Wednesday

Foghorn Therapeutics (NASDAQ:FHTX) is projected to release its Q1 2026 results before the market opens on Wednesday, May 13th. Analysts expect Foghorn Therapeutics to post earnings of ($0.28) per share and revenue of $7.9410 million for the quarter. Interested persons can check the company’s upcoming Q1 2026 earning summary page for the latest details on the call scheduled for Wednesday, May 13, 2026 at 9:30 AM ET.

Foghorn Therapeutics (NASDAQ:FHTX) last issued its quarterly earnings results on Wednesday, March 11th. The company reported ($0.34) earnings per share for the quarter, missing the consensus estimate of ($0.30) by ($0.04). The business had revenue of $9.25 million for the quarter, compared to analyst estimates of $9.50 million. On average, analysts expect Foghorn Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Foghorn Therapeutics Price Performance

Shares of NASDAQ:FHTX opened at $4.64 on Wednesday. Foghorn Therapeutics has a 1-year low of $3.27 and a 1-year high of $6.95. The company has a market capitalization of $272.41 million, a P/E ratio of -3.97 and a beta of 2.97. The firm’s 50 day simple moving average is $5.13 and its two-hundred day simple moving average is $5.05.

Analysts Set New Price Targets

Several brokerages have weighed in on FHTX. HC Wainwright reaffirmed a “buy” rating and set a $13.00 price target on shares of Foghorn Therapeutics in a report on Tuesday, March 10th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Foghorn Therapeutics in a report on Tuesday, April 21st. Wall Street Zen downgraded shares of Foghorn Therapeutics from a “buy” rating to a “hold” rating in a report on Saturday, March 14th. Jefferies Financial Group reissued a “buy” rating on shares of Foghorn Therapeutics in a report on Thursday, March 12th. Finally, Wedbush reissued an “outperform” rating and issued a $10.00 target price on shares of Foghorn Therapeutics in a report on Thursday, March 12th. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $11.13.

Hedge Funds Weigh In On Foghorn Therapeutics

Hedge funds have recently modified their holdings of the stock. Russell Investments Group Ltd. lifted its holdings in shares of Foghorn Therapeutics by 13,755.0% in the third quarter. Russell Investments Group Ltd. now owns 5,542 shares of the company’s stock worth $27,000 after buying an additional 5,502 shares in the last quarter. BNP Paribas Financial Markets lifted its holdings in shares of Foghorn Therapeutics by 48.0% in the third quarter. BNP Paribas Financial Markets now owns 7,103 shares of the company’s stock worth $35,000 after buying an additional 2,305 shares in the last quarter. Tower Research Capital LLC TRC lifted its holdings in shares of Foghorn Therapeutics by 136.8% in the second quarter. Tower Research Capital LLC TRC now owns 9,213 shares of the company’s stock worth $43,000 after buying an additional 5,323 shares in the last quarter. Occudo Quantitative Strategies LP purchased a new position in shares of Foghorn Therapeutics in the third quarter worth $58,000. Finally, Invesco Ltd. purchased a new stake in Foghorn Therapeutics during the fourth quarter valued at $58,000. Hedge funds and other institutional investors own 61.55% of the company’s stock.

About Foghorn Therapeutics

Foghorn Therapeutics is a clinical-stage biotechnology company focused on the discovery and development of novel epigenetic therapies for cancer. The company leverages its proprietary Targeted Protein Discovery Platform to identify and design small-molecule inhibitors that modulate chromatin regulatory proteins involved in tumor growth and survival. By targeting the mechanisms that control gene expression, Foghorn seeks to address unmet needs in oncology through precision medicine.

The company’s lead candidate, FHD-286, is a selective inhibitor of variant SWI/SNF chromatin remodeling complexes and is currently being evaluated in Phase 1 clinical trials for patients with solid tumors harboring specific SMARCA2 and SMARCA4 alterations.